Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
BIT
vs
S
S&P/ASX 300
BIT
Over the past 12 months, BIT has underperformed S&P/ASX 300, delivering a return of -71% compared to S&P/ASX 300's 3% drop.
Stocks Performance
BIT vs S&P/ASX 300
Performance Gap
BIT vs S&P/ASX 300
Performance By Year
BIT vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biotron Ltd
Glance View
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in Sydney, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The firm has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The firm also owns SedRx, which is a general anesthetic containing alfaxalone.